Where hair loss appears in the Trulicity® documents
The US label has two kinds of side-effect information. Section 6.1 gives rates from controlled trials; section 6.2 lists reactions reported voluntarily after approval, where the size of the exposed population is unknown. [1] Alopecia sits only in 6.2, under skin and subcutaneous tissue. The Canadian monograph places alopecia, with rash, itching and excessive sweating, in its list of less common trial events, again without numbers. [3] The EU table, built from trial frequencies and post-marketing reports, does not mention hair at all. [2]
| Document | What it says | Rate given? |
|---|---|---|
| US label, section 6.1 trial tables [1] | Not listed | No |
| US label, section 6.2 postmarketing [1] | Alopecia, skin and subcutaneous tissue | No; frequency cannot be estimated |
| Canadian monograph, section 8.3 [3] | Alopecia among less common trial events | No |
| EU summary, section 4.8 Table 1 [2] | Not listed | No |
How dulaglutide compares in research
A 2026 systematic review pooled 24 studies of GLP-1 medicines and hair loss. Semaglutide and tirzepatide showed the highest rates and the most frequent signals in drug-safety databases, while the fewer studies of liraglutide, dulaglutide, lixisenatide and exenatide generally found lower reported risk. [4] The reviewers point to rapid weight loss as a possible contributor, especially for the telogen effluvium type of shedding. [4]
Two analyses of the US adverse event reporting system point the same way. One, covering 2022 to 2025, found disproportionate alopecia reporting for semaglutide, with lower or non-significant signals for dulaglutide and tirzepatide. [5] Another, covering skin reactions from 2018 to 2024, found the highest rate of skin-related reports with semaglutide and the lowest with dulaglutide. [6] A third, across four international databases, found no class signal for hair loss, although semaglutide, liraglutide and dulaglutide were the three most reported medicines. [7] Voluntary reports reflect what people notice and report, not how often hair loss happens, so none of these studies proves the medicine causes it.
Why hair might shed on Trulicity®
- Weight loss: Trulicity® lowers appetite and body weight. In the 36-week dose study, people lost on average 3.0 kg on 1.5 mg, 3.8 kg on 3 mg and 4.6 kg on 4.5 mg. [1] Cleveland Clinic notes that rapid weight loss and restrictive diets can trigger telogen effluvium. [9] Whether the fairly modest weight change seen with Trulicity® explains its lower report rates has not been studied.
- Eating less: decreased appetite was reported by 4.9% on 0.75 mg and 8.6% on 1.5 mg, against 1.6% on placebo. [1] MedlinePlus lists crash diets, particularly those short of protein, among the causes of stress-related shedding. [8]
- Illness and other medicines: high fever, severe infection, major surgery and some common medicines, including beta-blockers, calcium channel blockers and NSAIDs, can set off shedding. [8] Many people with type 2 diabetes take several of these.
- Not the injection itself: no source describes a direct effect of dulaglutide on hair follicles. The postmarketing listing records reports; it does not explain a mechanism. [1]
Other causes worth ruling out
MedlinePlus explains that most people lose roughly 50 to 200 scalp hairs a day, and that hereditary thinning with age is the most common pattern. [8] Telogen effluvium can shed half to three quarters of scalp hair, often in handfuls when washing or combing, and may not be noticed until weeks or months after the stressful event. [8] Patchy bald spots suggest alopecia areata, and thyroid disease, anaemia, hormone changes, scalp infections and tight hairstyles are other causes. [8]
Cleveland Clinic adds that telogen effluvium usually begins two to three months after a trigger, lasts under six months in its acute form, and resolves in about 95% of cases. [9] That delay is why people starting Trulicity® often connect new shedding to the medicine, when the trigger may have been an illness, a stressful period or a change in eating several months earlier.
What the guidance describes
MedlinePlus says shedding linked to illness or medicine usually needs no treatment and grows back once the cause passes; hairstyles, hats or hair pieces can disguise thinning in the meantime. [8] Cleveland Clinic describes addressing the trigger, eating enough protein within a balanced, non-restrictive diet, managing stress and getting enough sleep, and asks you to check with a provider before starting supplements. [9]
If eating has dropped sharply on Trulicity®, mention it to your prescriber or a dietitian. The labels do not recommend any hair treatment or supplement for people on dulaglutide. [1][2]
Trulicity® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Hair loss with fatigue, weight gain, feeling cold or muscle weakness | Your doctor (thyroid and blood tests may be needed) | At your next appointment | MedlinePlus [8] |
| Patchy bald spots, or bald patches in the beard or eyebrows | Your doctor or a dermatologist | At your next appointment | MedlinePlus [8] |
| Pain, itching, redness or scaling of the scalp where hair is lost | Your doctor | At your next appointment | MedlinePlus [8] |
| Hair loss with acne, new facial hair or irregular periods | Your doctor | At your next appointment | MedlinePlus [8] |
| Heavy shedding that continues beyond six months | Your doctor | At your next appointment | Cleveland Clinic [9] |
